Atea Pharmaceuticals (AVIR) Net Margin (2021)
Atea Pharmaceuticals (AVIR) posted quarterly Net Margin of 60.95% for Q4 2021, up 170.93% quarter-over-quarter from 85.93% in Q3 2021.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Net Margin (2021) Analysis & Trends
Atea Pharmaceuticals' Net Margin history runs 1 years deep, the most recent figure standing at 60.95% for Q4 2021.
- In Q4 2021, Net Margin changed N/A year-over-year to 60.95%; the TTM figure through Dec 2021 stood at 34.49% (changed N/A YoY), while the FY2021 annual figure was 34.49%, up 5700.0% from the prior year.
- Net Margin for Q4 2021 stood at 60.95%, up from 85.93% in the prior quarter.
- The five-year high for Net Margin was 60.95% in Q4 2021, with the low at 85.93% in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 60.95% |
| Sep 30, 2021 | -85.93% |
| Jun 30, 2021 | 2.55% |
| Mar 31, 2021 | 46.55% |